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Abstract
Background: Solitary Fibrous Tumours (SFT) and haemangiopericytomas (HPC) are rare meningeal tumours that
have to be distinguished from meningiomas and more rarely from synovial sarcomas. We recently found that
ALDH1A1 was overexpressed in SFT and HPC as compared to soft tissue sarcomas. Using whole-genome DNA
microarrays, we defined the gene expression profiles of 16 SFT/HPC (9 HPC and 7 SFT). Expression profiles were
compared to publicly available expression profiles of additional SFT or HPC, meningiomas and synovial sarcomas.
We also performed an immunohistochemical (IHC) study with anti-ALDH1 and anti-CD34 antibodies on Tissue
Micro-Arrays including 38 SFT (25 meningeal and 13 extrameningeal), 55 meningeal haemangiopericytomas
(24 grade II, 31 grade III), 163 meningiomas (86 grade I, 62 grade II, 15 grade III) and 98 genetically confirmed
synovial sarcomas.
Results: ALDH1A1 gene was overexpressed in SFT/HPC, as compared to meningiomas and synovial sarcomas. These
findings were confirmed at the protein level. 84% of the SFT and 85.4% of the HPC were positive with anti-ALDH1
antibody, while only 7.1% of synovial sarcomas and 1.2% of meningiomas showed consistent expression. Positivity
was usually more diffuse in SFT/HPC compared to other tumours with more than 50% of tumour cells
immunostained in 32% of SFT and 50.8% of HPC. ALDH1 was a sensitive and specific marker for the diagnosis of
SFT (SE = 84%, SP = 98.8%) and HPC (SE = 84.5%, SP = 98.7%) of the meninges. In association with CD34, ALDH1
expression had a specificity and positive predictive value of 100%.
Conclusion: We show that ALDH1, a stem cell marker, is an accurate diagnostic marker for SFT and HPC, which
improves the diagnostic value of CD34. ALDH1 could also be a new therapeutic target for these tumours which are
not sensitive to conventional chemotherapy.
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Background
Solitary Fibrous Tumours (SFT) are ubiquitous mesenchy-
mal tumours. Carneiro et al. reported the first cases occu-
rring in the CNS in 1996 [1]. They usually arise in the
meninges, though a few cases have been described without
dural attachment. The histological features encompass a
patternless architecture with alternating hypocellular and
hypercellular areas. The hypocellular areas typically con-
tain thick bands of collagen, while the hypercellular areas
show staghorn vessels leading to a haemangiopericytoma
(HPC) pattern. In soft tissues, HPC is thought to be the
cellular variant of SFT [2,3]. However, SFT and HPC are
still listed as separate entities in the WHO classification
of CNS tumours [4,5] though we have reported their over-
lapping histological and immunohistological features,
suggesting a common spectrum [6]. In the CNS, SFT have
to be especially distinguished from meningiomas while
HPC have to be distinguished from meningeal sarcomas.
SFT lack the whorls, psammomas, nuclear-cytoplasmic in-
clusions and fibrous vessels present in meningiomas. The
nuclei are more hyperchromatic. Slit-like vascular spaces
are more common in SFT, but sometimes cellular elong-
ation and collagen production may simulate a fibrous
meningioma. More rarely, meningeal HPC can be con-
fused with a sarcoma harboring a haemangiopericytoma
pattern such as synovial sarcoma or mesenchymatous
chondrosarcoma. Synovial sarcomas are characterized by
a tumor-specific translocation t(X;18)(p11.2;q11.2) leading
to the SS18-SSX fusion gene [7-9]. The presence of cartil-
aginous islands is the obvious distinctive feature of mesen-
chymal chondrosarcoma. By immunohistochemistry (IHC),
SFT lack EMA expression, whereas they are usually
diffusely positive for CD34 as are meningeal HPC. Synovial
sarcomas and mesenchymal chondrosarcomas do not
usually express CD34. On the other hand, meningiomas
can only react to a limited extent with CD34 and widely
express EMA. Thus, the CD34 positivity of SFT is non-
specific and non-constant, calling for the identification of
more accurate diagnostic molecular markers.
Using whole-genome oligonucleotide microarray, we
recently identified a list of 3,401 genes differentially
expressed between SFT/HPC (n = 29) and Soft Tissue
Sarcomas (STS) (n = 179), including synovial sarcomas
(Bertucci et al., manuscript in preparation). Among
them, the ALDH1A1 gene was among the top two genes
overexpressed in SFT/HPC with a fold change (FC) be-
tween mean expression levels in SFT/HPC versus STS
equal to 34. ALDH1 is a cytosolic detoxifying enzyme
responsible for the oxidation of intracellular aldehydes.
It is also highly expressed in hematopoietic progenitors
where it is linked to retinoid metabolism with a role in
early differentiation of stem cells. In search of a diag-
nostic value, we have performed an immunohistoche-
mical study with antibody anti-ALDH1 in 243 meningeal
tumours that encompassed: 25 CNS WHO SFT, 55 CNS
WHO HPC and 163 meningiomas on Tissue MicroArrays.
This was compared to ALDH1 expression of 98 synovial
sarcomas and 13 extrameningeal SFT. We tested the hy-
pothesis that ALDH1 expression could help to distinguish
meningeal SFT or HPC from meningiomas or synovial
sarcomas. We compared its expression at both the mRNA
and protein levels using respectively gene expression data
and IHC data on Tissue MicroArrays (TMA). We also
compared ALDH1 immunohistochemical expression to
CD34, the most consistently expressed antigen in SFT
and HPC.
Results
ALDH1A1 mRNA is overexpressed in SFT/HPC as
compared to synovial sarcomas and meningiomas
Normalised RNA expression level of ALDH1A1 was avail-
able for 52 SFT/HPC, 161 meningiomas and 30 synovial
sarcomas. As shown in Figure 1. ALDH1A1 expression was
significantly higher in SFT/HPC as compared with synovial
sarcomas (p = 9.4E-08, t-test) with a mean fold change
(FC) equal to 9.5. Similarly, ALDH1A1 expression was
significantly higher in SFT/HPC as compared with men-
ingiomas (p = 1.8E-06, t-test) with a mean FC equal to 3.
Interestingly, ALDH1A1 mRNA expression was higher
in the 20 meningeal tumours than in the 32 extra-
meningeal tumours (p = 7.5E-4; t-test). We thus repeated
the comparative analysis using only meningeal tumours.
Differences between meningeal SFT/HPC and other histo-
logical types were even more significant than before
(Figure 1); the FC between SFT/HPC and synovial sarcoma
increased to 20.2 (p = 1.2E-10, t-test) and between SFT/
HPC and meningiomas increased to 6.4 (p = 6.7E-9, t-test).
Thus, at the mRNA level, SFT/HPC, and especially the
meningeal locations, showed higher ALDH1A1 expres-
sion than synovial sarcomas and meningiomas.
No significant difference was observed between SFT
and HPC. By contrast, significant differences were ob-
served between SFT/HPC and synovial sarcomas and
meningiomas. We found similar results when analyses
were applied to the 12 meningeal tumours only. Results
are shown in Additional file 1: Table S2A and 2B.
ALDH1 immunostaining
Solitary fibrous tumors and haemangiopericytomas
(Table 1)
84% of meningeal, 84.6% of extrameningeal SFT and
85.4% of HPC were positive with anti-ALDH1 antibody
on TMA. Among HPC 75% of grade II and 93.5% of
grade III were positive. Most SFT (72%) showed inter-
mediate positivity (10 cases, 40%) or high positivity
(8 cases, 32%) while 50.1% of HPC had high positivity
(Figure 2a-b). ALDH1 immunostaining data were statis-
tically not different between SFT and HPC though a
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tendency for having a more diffuse positivity was seen
in grade III HPC (p = 0.118).
Protein expression by IHC was not statistically higher
in meningeal tumours than extra-meningeal tumours,
unlike what was observed at the mRNA level (Figure 1)
(p = 1 for comparing positive and negative cases and
p = 0.501 for semi-quantitative analysis).
Meningiomas and synovial sarcomas (Table 2)
Most meningiomas (98.8%) and synovial sarcomas
(92.9%) lack ALDH1 expression by immunohistochem-
istry (Figure 2c-d). Among meningiomas, only two cases
(1.2%) were positive for ALDH1. They were both grade
II. One had low positivity, while the other one showed
intermediate positivity. These cases were reviewed and
showed typical histological features of fibroblastic men-
ingiomas. They both expressed EMA. Seven synovial
sarcomas (7.1%) expressed ALDH1 by IHC, with low
positivity in 3 cases and high positivity in 4 cases.
CD34 immunostaining
Solitary fibrous tumors and haemangiopericytomas
(Table 2)
92% of meningeal SFT and 74.5 of meningeal HPC were
positive for CD34.
Meningiomas and synovial sarcomas (Table 2)
Among meningiomas, 5 grade I samples and 3 grade II
samples were CD34-positive (4.9%). Six were fibroblastic
and 2 were psammomatous. Five had low positivity. Two
had intermediate and one had high positivity. These
three meningiomas were all fibroblastic and showed
EMA positivity. CD34 immunoreactivity was never ob-
served in synovial sarcomas.
Diagnostic value of ALDH1 and CD34 immunostaining
(Table 3)
We found that ALDH1 and CD34 were expressed in
most meningeal SFT and HPC in contrast to meningi-
omas. As shown in Table 2, most SFT (20 of 25) and HPC
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Figure 1 mRNA expression of ALDH1A1 in tumour samples. ALDH1A1 expression across tumor samples profiled using DNA microarrays. Log2-
transformed expression levels in tumors are reported as a box plot according to histological type: SFT, solitary fibrous tumour; HPC, Haemangiopericytoma;
M, meningioma; SVS, synovial sarcoma; meningeal SFT and extra-meningeal SFT. Median and ranges are indicated. *** means p < 0.001 (t-test).
Table 1 ALDH1 IHC data for SFT (meningeal and extrameningeal) and meningeal HPC
ALDH1
negative
ALDH1
positive
ALDH1
5-10%
ALDH1
11-50
ALDH1
>50%
Meningeal HPC grade II n = 24 6 18 5 2 11
n = 55 grade III n = 31 2 29 5 7 17
Meningeal SFT 4 21 3 10 8
n = 25
Extrameningeal SFT 2 11 3 4 4
n = 13
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(34 of 55) were positive for both markers, while no men-
ingiomas or synovial sarcomas were. 4 additional SFT and
20 HPC were positive for ALDH1 or CD34. Only one case
of SFT was negative for both markers. However, at recur-
rence the tumour showed ALDH1 and CD34 positivity.
One additional grade II HPC was negative for the two
markers. Both tumours had no SYT rearrangement on
FISH analysis. Therefore 24/25 (96%) meningeal SFT and
54/55 (98%) meningeal HPC expressed ALDH1 and or
CD34 whereas only 10 /163 (6%) meningiomas and 7/98
(7%) synovial sarcomas did.
No statistically significant difference was seen when
comparing sensitivity (SE) and specificity (SP) of each
immunohistochemical marker (ALDH1 or CD34), for
the diagnosis of SFT versus meningioma (p = 0.617 for
SE and p = 0.114 for SP) or HPC versus meningioma
(p = 0.264 for SE and p = 0.114 for SP). However,
ALDH1 had a tendency for being more sensitive than
CD34 in the group of grade III HPC (p = 0.07).
We then tested the diagnostic value of combined
ALDH1 and CD34 IHC staining. 94% of meningiomas
and 93% of synovial sarcomas were negative for both
markers while 80% of SFT and 62% of HPC were posi-
tive. We thus found that the double positivity for CD34
and ALDH1 was highly specific for the diagnosis of SFT,
with a specificity and positive predictive value of 100%.
Discussion
SFT are newly described tumours in the CNS. Diagnosis
is based on histological features according to the WHO
classification: such as “a pattern-less architecture charac-
terized by a combination of alternating hypocellular and
hypercellular areas separated from each other by thick
bands of hyalinized somewhat keloidal collagen and
branching haemangiopericytoma-like vessels” [5]. As the
main location is the meninges, they have to be distin-
guished from other meningeal tumours, especially fibro-
blastic meningiomas. A high cellularity in some SFT and
in HPC may also suggest a sarcoma, especially synovial
sarcomas because of their “haemangiopericytoma” vascu-
lar pattern. We have performed the most extensive FISH
study on TMA of meningeal SFT and HPC in search of
SYT rearrangement. No rearrangement was found, su-
ggesting that no misdiagnosed synovial sarcomas were in-
cluded in the series. CD34 antigen is the most consistent
immunohistochemical marker of SFT or HPC. However,
it lacks specificity being expressed by endothelial cells,
hematopoietic progenitor cells, and a lot of solid tumours
such as gastrointestinal stromal tumours, vascular tu-
mours, or dermatofibrosarcoma protuberans [10-17]. In
addition, CD34 is variably expressed in SFT/HPC with
some tumours showing focal or weak positivity or being
negative [18-20]. Other immunohistochemical markers
expressed by SFT such as bcl2, CD99, FXIII are less spe-
cific than CD34 [21].
Cytogenetic studies failed to show consistent recurrent
abnormalities in SFT or HPC of any location. Very few
transcriptomic studies of SFT/HPC are available in the
literature [22,23]. We have performed an extensive menin-
geal SFT/HPC gene profiling study and showed that, at
the mRNA level these tumours, and particularly menin-
geal, had higher ALDH1A1 expression than synovial
sarcomas and meningiomas. This was consistent with a
previous study by Hajdu et al. who showed high mRNA
expression of ALDH1A1 in SFT including meningeal cases
Table 2 ALDH1 and CD34 data for meningeal SFT and
HPC, meningiomas and synovialosarcomas
ALDH1+
CD34+
ALDH1+
CD34-
ALDH1-
CD34+
ALDH1+
and or
CD34+
ALDH1-
CD34-
SFT 20 1 3 24 1
n = 25
Grade II HPC 14 4 5 23 1
n = 24
Grade III HPC 20 9 2 31 0
n = 31
meningiomas 0 2 8 10 153
n = 163
Synovialosarcomas 0 7 0 7 91
n = 98
Figure 2 ALDH1 immunohistochemistry on TMA (X10). Diffuse
expression of ALDH1 in a SFT (a) and meningeal HPC (b). No
expression of ALDH1 in a monophasic fusiform cell synovial sarcoma
(c) and a transitional Grade I meningioma (d).
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but no immunohistochemical study was performed. These
results were further extended by IHC in a larger series of
samples including 38 SFT (25 meningeal and 13 extra-
meningeal), 55 HPC, 163 meningiomas and 98 synovial
sarcomas. ALDH1 immunostaining was highly specific for
meningeal SFT/HPC diagnosis as only 1.2% of meningi-
omas and 7.1% of synovial sarcomas were positive. Com-
pared to CD34 staining, ALDH1 sensitivity, specificity,
positive and negative predictive values were not statisti-
cally significantly different. However sensitivity of ALDH1
immunostaining was slightly better than CD34 (p = 0.07)
especially for grade III HPC and could be especially useful
in this category of tumours. More interestingly, the com-
bined CD34 and ALDH1 expression by IHC was highly
suggestive of the SFT or HPC diagnosis with a specificity
and positive predictive value of 100%.
ALDH1A1 belongs to the ALDH enzymes, a family of
evolutionarily conserved enzymes comprised of 19 isoforms
that are localized in the cytoplasm, mitochondria or
nucleus [24]. They are responsible for oxidizing aldehydes
to carboxylic acids. ALDH1A1 is one of the 6 ALDH1
isoforms, the others being ALDH1A2, ALDH1A3,
ALDH1B1, ALDH1L1, ALDH1L2 [24]. It was recently
suggested that the different isoforms of ALDH could be
tumour-specific with diagnostic implications. ALDH1A1
is predominantly expressed in the epithelium of testis,
brain, eye, liver, kidney, neural and hematopoietic stem
cells [25,26]. We have shown that ALDH1A1 was
overexpressed in SFT and HPC versus potential menin-
geal mimics. By immunohistochemistry ALDH1 was
highly expressed in these tumours, however the anti-
body we used might not be entirely specific to the iso-
form ALDH1A1.
ALDH1 plays a major role in the biosynthesis of retinoic
acid (RA) from retinol. It is this function that links
ALDH1 to the “stemness” characteristics of the Cancer
Stem Cells (CSC) since RA is a regulator of cellular prolif-
eration, differentiation, apoptosis and survival. ALDH1 ex-
pression has been found in hematopoietic and epithelial
cancers. Recently the presence of increased ALDH1 activ-
ity in a subpopulation of the human sarcoma cell line was
also demonstrated [27,28]. These cells had stem cell prop-
erties since they were able to form spheres in anchorage-
independent, serum-starved conditions, and showed high
expression level of several stem cell genes such as Nanog,
Oct3/4, Stat3 and Sox2. It is quite intriguing that the most
consistent diagnostic markers for SFT and HPC, CD34
and ALDH1, are stem cell markers. These data could have
histogenetic significance. The cell of origin of these tu-
mors is unknown but is thought to be mesenchymal in
nature [1]. High ALDH1 and CD34 expression also sug-
gests an immature undifferentiated state.
In addition to its diagnostic interest, high ALDH1 ex-
pression in SFT and HPC also has therapeutic implica-
tions. It could be responsible in part for the failure of
conventional chemotherapy, as has been suggested for
other malignancies such as breast cancer [29-31], colon
cancer [32] or medulloblastoma [33]. Indeed, ALDH1A1
is known to metabolize and detoxify chemotherapeutic
agents such as cyclophosphamide [34] and ifosfamide
[35]. On the other hand, ALDH1 emerges as a new
therapeutic target as specific inhibitors of ALDH such as
DEAB (4-diethylaminobenzaldehyde) exist [24,36].
Recently, two different teams identified recurrent
NAB2-STAT6 gene fusions on chromosome 12q13 in
Solitary Fibrous Tumours of various locations [37,38].
Robinson et al. identified a NAB2-STAT6 gene fusion in
a hepatic metastasis of a malignant meningeal SFT by
integrative sequencing. NAB2-STAT6 gene fusion was
also found in 27 additional SFT including 3 meningeal
tumours [38]. Chmielecki et al. found 7 variants of this
fusion transcript in 29/53 SFT (55%) [37]. NAB2-STAT6
gene fusion is the first recurrent molecular feature
reported in SFT. Further studies are required to confirm
its diagnostic value especially it would be very interest-
ing to compare the sensitivity and specificity of ALDH1
overexpression to NAB2-STAT6 gene fusion. It would
also be very interesting to search for NAB2-STAT6 gene
Table 3 Impact value of ALDH1 and CD34 IHC for the diagnosis of meningeal SFT or HPC versus meningioma
SE CI 95% SP IC 95% PPV IC 95% NPV IC 95%
ALDH1
TFS n = 25 84% 0.63-0.94 98.8% 0.95-0.99 91.3% 0.7-0.98 97.6% 0.93-0.99
HPC = 55 85.4% 0.73-0.93 98.7% 0.95-0.99 95.9% 0.84-0.99 95.2% 0.9-0.97
CD34
TFS n = 25 92% 0.72-0.98 95% 0.9-0.97 74.2% 0.55-0.87 98.7% 0.94-0.99
HPC n = 55 74.5% 0.61-0.85 95% 0.9-0.97 83.7% 0.69-0.92 91.7% 0.86-0.95
ALDH1 and CD34+
TFS n = 20 80% 0.58-0.92 100% 0.97-1 100% 0.79-1 97% 0.93-0.99
HPC n = 34 62% 0.48-0.74 100% 0.97-1 100% 0.87-1 88% 0.83-0.93
SE: sensitivity, PPV: positive predictive value.
SP: specificity, NPV: negative positive value.
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fusion in a large cohort of both meningeal SFT and HPC
to definitively determine the relationship between these
tumours.
Conclusion
We have found that SFT and HPC displayed high
ALDH1A1 expression at the mRNA level compared to
meningiomas and synovial sarcomas. By IHC, ALDH1 was
an accurate marker for the diagnostic of SFT and HPC.
This new marker had a high sensitivity and specificity that
improves the diagnostic value of CD34. We recommend
its use in routine practice in association with CD34.
Methods
Gene expression data sets of SFTs
To determine ALDH1A1 mRNA expression in SFT/HPC,
we first analyzed gene expression data recently generated
by our laboratory (IPC, Marseille, France) from frozen
tumor samples (APHM Biobank authorization number
2008/70, NeurobiotecBank, Sainte Anne Hospital CRB
NSPN authorization number AC-2008-82, La Pitié
Salpétrière Biobank) collected from 16 patients who
underwent initial surgery and/or diagnostic biopsy. The
origin of samples was meningeal in 12 cases (9 HPC and 3
SFT according to the CNS WHO classification) and extra-
meningeal in 4 cases (3 conventional Soft tissue SFT and
one cellular variant so called “HPC”). All profiled speci-
mens contained more than 70% of cancer cells (as
assessed before RNA extraction using frozen sections ad-
jacent to the profiled samples). Each patient gave written
informed consent for molecular analysis, and the study
was approved by our institutional ethics committee. Ex-
pression profiles were established for these 16 samples
with Affymetrix U133 Plus 2.0 human microarrays
(Affymetrix®, Santa Clara, CA, USA) as previously de-
scribed [39]. All data are MIAME compliant and the
raw data will be publicly available after acceptance of
the paper.
To increase the size of the SFT series, we collected
two publicly available data sets: West’s set [23] collected
from (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE4305) and including 13 SFTs and 30 STS pro-
filed using 42,000-element cDNA microarrays, and
Hajdu’s set [22] collected from (http///cbio.mskcc.org/
Public/SFT) and including 23 SFTs and 33 STS profiled
using Affymetrix U133A microarrays. Whole-genome
RNA expression profiles were thus available for 52 SFT/
HPC samples, including 20 meningeal cases and 32
extra-meningeal cases. However, in the study of Hajdu
et al., the meningeal cases encompassed 6 malignant
SFT. Because of the rarity of this diagnosis in meningeal
location some of these tumours might have the histo-
logical criteria of HPC according to the CNS WHO
classification of brain tumours. So we used the termin-
ology SFT/HPC for meningeal tumours.
Gene expression data sets of synovial sarcomas and
meningiomas
To analyze ALDH1A1 mRNA expression in synovial sar-
comas and meningiomas, we collected publicly available
gene expression data sets. For meningiomas, we collected
three data sets including a total of 161 samples: Claus’s set
[40] collected from the National Center for Biotechnology
Information (NCBI)/Genbank GEO database (series entry
GSE9438) and including 31 samples, Lee’s set [41] col-
lected from the GEO database (GSE16581) and including
68 samples, and Scheck’s set collected from the GEO data-
base (GSE4780) and including 62 samples.
For synovial sarcomas, we collected four data sets in-
cluding a total of 30 samples: Nakayama’s set [42] from
the GEO database (GSE6481) and including 16 cases,
Detwiller’s set [43] from the GEO database (GSE16581)
and including 4 cases, West’s set [23] collected from
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=G
SE4305) and including 6 cases, and Hajdu’s set [22] col-
lected from (http///cbio.mskcc.org/Public/SFT) and in-
cluding 4 cases.
Analysis of gene expression data
All gene expression data sets are listed in Additional
file 2: Table S1. RNA expression data were thus avail-
able for 52 SFT/HPC, 161 meningiomas and 30 synovial
sarcomas, collected through 8 data sets. Before analysis,
we first applied quantile normalization to the available
processed West’s data set and MAS5-processed
Detwiller and Nakayama’s Affymetrix data sets. For the
other Affymetrix sets (raw data), we used Robust
Multichip Average (RMA) [44] with the non-parametric
quantile algorithm as normalization parameter. Quantile
normalization or RMA was done in R using Bioconductor
and associated packages.
Normalised expression data generated from different
technological platforms and laboratories were then fur-
ther processed to eliminate potential bias. Processing of
data included as first step the selection of genes unique
and common to all sets. We focused on ALDH1A1 and
a list of 575 human housekeeping genes [45]. Before the
selection, we mapped hybridization probes across the
different technological platforms (Affymetrix U133A
and U133 Plus 2.0, and Stanford cDNA microarrays).
Affymetrix gene chip annotations were updated using
NetAffx Annotation files (www.affymetrix.com; release
from 01/12/2008). Stanford gene annotations were re-
trieved and updated using EntrezGene (Homo sapiens
gene information db, release from 09/12/2008, ftp://ftp.
ncbi.nlm.nih.gov/gene/). All probes were then mapped
on the basis of their EntrezGeneID. When multiple
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probes were mapped to the same GeneID, the one with
the highest variance in a particular dataset was selected
to represent the GeneID. For redundant Affymetrix probe
sets, those with an extension « _at », next « s_at », and
followed by all other extensions were preferentially kept.
After mapping and selection, 451 out of the 575 house-
keeping genes were retained. Among these 451 genes, we
then selected the ones with the smallest variation in RNA
expression across all data sets: 354 genes were retained,
showing the smallest inter-set variance of intra-set vari-
ance, the cut-off of non-variance being defined by the
distribution of variability measurements. The last step was
the normalisation of all data sets based on 355 genes
including the 354 housekeeping genes and ALDH1A1
(Affymetrix probe set 212224_at, and IMAGE clone
855624 for West’s set) using Distance Weighted Discrim-
ination (DWD) [46]. Principal Component Analysis (PCA)
demonstrated that normalization was effective in remo-
ving technical, inter-laboratory variation in gene expres-
sion (data not shown), allowing us to compare ALDH1A1
expression between all data sets. Comparison was done
using continuous values.
Then, we compared (Mann–Whitney test) the ALDH1A1
mRNA expression of HPC (N = 10) vs SFT (N = 6),of HPC
(N= 10) vs synovial sarcomas (N = 30) and vs meningiomas
(N = 161), and of SFT (N= 6) vs synovial sarcomas (N = 30)
and vsmeningiomas (N = 161).
Immunohistochemistry
A total of 38 SFT (25 meningeal and 13 extrameningeal),
55 meningeal HPC, 163 meningiomas and 98 synovialo-
sarcomas were selected for the IHC study. The eighty
cases of SFT/HPC belonged to a previously published
multicentric retrospective study [6]. The thirteen extra-
meningeal SFT were located in soft tissues (9 cases) and
the thorax (3 cases). The absence of t(X;18) in SFT sam-
ples was checked using a previously described FISH
method [8] with the SS18 Break apart FISH probe Kit
from Vysis:. 78 cases of 93 SFT were interpretable and did
not show any SYT rearrangement. Meningiomas were
retrieved from the pathological archives of the Timone
Hospital. They included 86 grade I tumors, 62 grade II,
and 15 grade III. Among the grade I there were 37
meningothelial, 27 fibroblastic, 14 transitional, 5 psamom-
matous, 2 secretory and one microcystic sub-types. A total
of 98 genetically confirmed synovial sarcomas were
provided from the pathological files of the The Institut
Bergonié (Bordeaux).
Automate immunohistochemistry was performed on
formol fixed paraffin embedded 4 μm sections from TMA
paraffin blocks. All tumor specimens had been fixed in 4%
formalin. TMAs were prepared as previously described
[47]. Briefly, for each sample, three representative sample
areas were carefully selected from a haematoxylin–eosin-
stained section of a donor block, in order to punch core
cylinders with a diameter of 0.6 mm (for SFT and men-
ingiomas) and 1 mm for synovial sarcomas. Each tumour
was punched from three representative areas and depo-
sited into two separate recipient paraffin blocks using a
specific arraying device (Alphelys). Automate IHC was
performed using a Ventana automate (Benchmark XT,
Ventana Medical Systems SA, Illkirch, France) and the
two following antibodies: ALDH1 (clone 44/ALDH, im-
munogen Human ALDH1 aa. 7–128, BD Transduction
Laboratories, dilution: 1/500), and CD34 (QBEND10,
prediluted). One hour Heat antigen retrieval at 95° was
used with a citrate buffer pH = 8.4 for ALDH1 and EDTA
buffer pH = 8 for CD34. External positive control was a
glioblastoma for ALDH1. For CD34, normal vessels serve
as internal positive control. Negative controls corres-
ponded to omission of primary antibody or irrelevant
antibodies of the same isotype. IHC was recorded positive
when cytoplasmic staining was observed in 5% or more of
the cells for both markers. Then a semi-quantitative ana-
lysis was done for ALDH1-positive specimens. A mean of
the percentage of each spot was recorded and classified as
follows: low positivity = 5-10% of stained cells, intermedi-
ate positivity = 11-50%, high positivity > 50%.
Statistical analyses
Comparison of ALDH1A1 mRNA expression status accor-
ding to histological type was done using the Student t-test
applied to continuous values.
For immunohistochemistry, continuous variables are
expressed as means ±SD or as median with range (min,
max), and categorical variables are reported as count and
percentages. Comparisons of means values between two
groups were performed using student t-test or Mann–
Whitney U. Comparisons of percentages were performed
using Chi-Square test or (Fisher’s exact test, as appro-
priate). The discriminative ability of ALDH1 and CD34
immunostaining was quantified by the measures of diag-
nostic accuracy. All statistical tests were two-sided at the
5% level of significance. Statistical analysis was done using
PASW Statistics version 17.02 (IBM SPSS Inc., Chicago,
IL, USA) and R software. Sensitivity and specificity of
ALDH1 and CD34 immunostainings were compared as
previously reported [48].
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